DARE Stock Analysis: Buy, Sell, or Hold?
DARE - Dare Bioscience, Inc. Common Stock
$0.76
0.03 (3.54%)
▲
5d:
-5.05%
30d:
-37.62%
90d:
-65.25%
HOLD
LOW Confidence
Analysis Updated: Aug 31, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When DARE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: DARE shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: DARE shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: DARE is currently trading at $0.76, which is considered oversold relative to its 30-day fair value range of $0.83 to $1.35. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.8) compared to its historical average (3.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DARE is in a strong downtrend. Immediate support is located at $0.72, while resistance sits at $0.86. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: DARE scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.33 (+995.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DARE is in a strong downtrend. Immediate support is located at $0.72, while resistance sits at $0.86. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: DARE scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.33 (+995.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.83 -
$1.35
Company Quality Score
56/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 995.0% below Wall St target ($8.33)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 43% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-5.1%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.83 -
$1.35
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.72
Resistance Level
$0.86
Current Trend
Strong Downtrend
Technical data as of
Aug 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.83
Wall Street Target
$8.33
(+995.0%)
Revenue Growth (YoY)
499.6%
PE vs Historical
-1.8 vs 3.6
CHEAP
Share & Embed Analysis
Last updated: August 31, 2026 7:44 PM ET
Data refreshes hourly during market hours. Next update: 8:44 PM
Data refreshes hourly during market hours. Next update: 8:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DARE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 40 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 41 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 26 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$287 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 46 HOLD |
